Literature DB >> 18215115

Pathogenesis of thrombotic microangiopathies.

X Long Zheng1, J Evan Sadler.   

Abstract

Profound thrombocytopenia and microangiopathic hemolytic anemia characterize thrombotic microangiopathy, which includes two major disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). TTP has at least three types: congenital or familial, idiopathic, and nonidiopathic. The congenital and idiopathic TTP syndromes are caused primarily by deficiency of ADAMTS13, owing to mutations in the ADAMTS13 gene or autoantibodies that inhibit ADAMTS13 activity. HUS is similar to TTP, but is associated with acute renal failure. Diarrhea-associated HUS accounts for more than 90% of cases and is usually caused by infection with Shiga-toxin-producing Escherichia coli (O157:H7). Diarrhea-negative HUS is associated with complement dysregulation in up to 50% of cases, caused by mutations in complement factor H, membrane cofactor protein, factor I or factor B, or by autoantibodies against factor H. The incomplete penetrance of mutations in either ADAMTS13 or complement regulatory genes suggests that precipitating events or triggers may be required to cause thrombotic microangiopathy in many patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215115      PMCID: PMC2582586          DOI: 10.1146/annurev.pathmechdis.3.121806.154311

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  163 in total

1.  Complement factor H and the haemolytic uraemic syndrome.

Authors:  C M Taylor
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

2.  Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes.

Authors:  J N George; G B Selby
Journal:  Bone Marrow Transplant       Date:  2004-06       Impact factor: 5.483

3.  Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency?

Authors:  Soraya Krieg; Jan-Dirk Studt; Irmela Sulzer; Bernhard Lämmle; Johanna A Kremer Hovinga
Journal:  Thromb Haemost       Date:  2005-12       Impact factor: 5.249

Review 4.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.

Authors:  M Furlan; B Lämmle
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

5.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

6.  Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.

Authors:  Y Sugio; T Okamura; K Shimoda; M Matsumoto; H Yagi; H Ishizashi; Y Niho; S Inaba; Y Fujimura
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

7.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Authors:  P M Mannucci; M T Canciani; I Forza; F Lussana; A Lattuada; E Rossi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

8.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.

Authors:  Arnoldo Padilla; Joel L Moake; Aubrey Bernardo; Chalmette Ball; Yongtao Wang; Maneesh Arya; Leticia Nolasco; Nancy Turner; Michael C Berndt; Bahman Anvari; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 9.  Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.

Authors:  James N George; Xiaoning Li; Jay R McMinn; Deirdra R Terrell; Sara K Vesely; George B Selby
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

10.  An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations.

Authors:  Wenhua Zhou; Han-Mou Tsai
Journal:  Thromb Haemost       Date:  2004-04       Impact factor: 5.249

View more
  63 in total

1.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 2.  Recent Insights Into the Regulation of Coagulation and Thrombosis.

Authors:  Xian Li; Martha M S Sim; Jeremy P Wood
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-22       Impact factor: 8.311

3.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

4.  [Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].

Authors:  T Schmidt; D A Tsakiris; M Grapow; M Siegemund
Journal:  Anaesthesist       Date:  2010-12-25       Impact factor: 1.041

5.  [Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination].

Authors:  Regina Hermann; Alexander Pfeil; Martin Busch; Christiane Kettner; Daniel Kretzschmar; Andreas Hansch; Paul La Rosée; Gunter Wolf
Journal:  Med Klin (Munich)       Date:  2010-09-28

Review 6.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 7.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

Review 8.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

9.  Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.

Authors:  Corentin Orvain; Jean-François Augusto; Virginie Besson; Guillaume Marc; Paul Coppo; Jean-François Subra; Johnny Sayegh
Journal:  Int Urol Nephrol       Date:  2013-02-24       Impact factor: 2.370

10.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.